Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Naoto Kawabe is active.

Publication


Featured researches published by Naoto Kawabe.


Hepatology Research | 2009

Liver stiffness measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C

Yoshifumi Nitta; Naoto Kawabe; Senju Hashimoto; Masao Harata; Naruomi Komura; Kyoko Kobayashi; Yuko Arima; Hiroaki Shimazaki; Takuji Nakano; Michihito Murao; Naohiro Ichino; Keisuke Osakabe; Hisako Aoki; Yoko Hosoe; Hiroko Sugiyama; Toru Nishikawa; Kentaro Yoshioka

Aim:  Liver stiffness (LS) measured by transient elastography (TE) has been reported to correlate with liver fibrosis, which is usually semiquantitatively assessed. In the present study, the fibrosis area was measured by image analysis software in liver biopsy specimens and its correlation with LS was assessed.


Hepatology Research | 2010

Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C

Yuko Arima; Naoto Kawabe; Senju Hashimoto; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Kyoko Kobayashi; Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Akihiko Okumura; Tetsuya Ishikawa; Kentaro Yoshioka

Aim:  To assess the regression of liver fibrosis after interferon (IFN) treatment in patients with chronic hepatitis C, liver stiffness (LS) was measured repeatedly and the factors associated with reduction of LS were assessed.


Hepatology Research | 2008

Transient elastography: Applications and limitations

Kentaro Yoshioka; Naoto Kawabe; Senju Hashimoto

Transient elastgraphy with use of FibroScan is one of most accurate methods for assessment of liver fibrosis. FibroScan can be readily used with an operator with a short training. In many different studies, liver stiffness measured by transient elastgraphy correlates well with fibrosis stages, and cutoff values of liver stiffness for fibrosis staging are similar even among different diseases. However there is wide variation of stiffness values in the same fibrosis stage, and some overlap between the adjacent stages. In addition, inflammatory activity and size of nodule of cirrhosis affect the liver stiffness values. The reproducibility may be reduced by age, obesity, steatosis, narrow intercostal space and lower degrees of hepatic fibrosis in patients. Thus the estimation of fibrosis stages from liver stiffness should be cautiously done. To improve the accuracy of liver fibrosis staging, the combination of transient elastography with other noninvasive methods such as FibroTest should be required.


Hepatology Research | 2011

Liver stiffness in extrahepatic cholestasis correlates positively with bilirubin and negatively with alanine aminotransferase

Masao Harata; Senju Hashimoto; Naoto Kawabe; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Arima; Hiroaki Shimazaki; Tetsuya Ishikawa; Akihiko Okumura; Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Kentaro Yoshioka

Aim:  Transient elastography is a non‐invasive tool to measure liver stiffness (LS), which has been reported to correlate with stage of liver fibrosis. Extrahepatic cholestasis was reported to cause elevated LS, which is considered to be attributed to the increased hydrostatic pressure in the liver. In the present study, the correlation of LS with laboratory data was investigated in extrahepatic cholestasis. The change of LS after biliary drainage was also assessed.


Hepatology Research | 2015

Measurement of liver stiffness as a non‐invasive method for diagnosis of non‐alcoholic fatty liver disease

Kentaro Yoshioka; Senju Hashimoto; Naoto Kawabe

Non‐alcoholic fatty liver disease (NAFLD) is one of the major causes of liver disease worldwide. To detect early stages of NAFLD and start treatment or to monitor the changes in trials of new drugs, non‐invasive diagnostic methods are needed, such as biochemical markers or liver stiffness measurement (LSM). LSM with transient elastography (TE) and acoustic radiation force impulse (ARFI) has been shown to be useful in NAFLD, although the cut‐off values have varied among reports. Magnetic resonance elastography and real‐time tissue elastography also can be useful for the diagnosis of NAFLD, although the number of studies is limited. Fibrosis is absent in 8–40% of patients with non‐alcoholic steatohepatitis (NASH), making it difficult to diagnose NASH by LSM because LSM is usually associated with fibrotic stage. The presence of inflammation or hepatocyte ballooning may affect LSM and aid the diagnosis of NASH without fibrosis. However, obesity significantly increases the failure of LSM and its interference is more conspicuous in TE than in ARFI. The newly implemented XL probe of TE has overcome the difficulty to some degree. Nonetheless, the effects of obesity, hepatocyte ballooning, steatosis and inflammation on LSM values have not yet been adequately investigated, although they are likely to affect LSM values. Further studies are needed to establish the clinical utility of LSM in NAFLD.


World Journal of Gastroenterology | 2014

Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C.

Toru Nishikawa; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Mizuno; Hiroaki Shimazaki; Toshiki Kan; Kazunori Nakaoka; Yuka Takagawa; Masashi Ohki; Naohiro Ichino; Keisuke Osakabe; Kentaro Yoshioka

AIM To investigate the factors other than fibrosis stage correlating with acoustic radiation force impulse (ARFI) elastograpy in chronic hepatitis C. METHODS ARFI elastograpy was performed in 108 consecutive patients with chronic hepatitis C who underwent a liver biopsy. The proportion of fibrosis area in the biopsy specimens was measured by computer-assisted morphometric image analysis. RESULTS ARFI correlated significantly with fibrosis stage (β = 0.1865, P < 0.0001) and hyaluronic acid levels (β = 0.0008, P = 0.0039) in all patients by multiple regression analysis. Fibrosis area correlated significantly with ARFI by Spearmans rank correlation test but not by multiple regression analysis. ARFI correlated significantly with body mass index (BMI) (β = -0.0334, P = 0.0001) in F 0 or F 1, with γ-glutamyltranspeptidase levels (β = 0.0048, P = 0.0012) in F 2, and with fibrosis stage (β = 0.2921, P = 0.0044) and hyaluronic acid levels (β = 0.0012, P = 0.0025) in F 3 or F 4. The ARFI cutoff value was 1.28 m/s for F ≥ 2, 1.44 m/s for F ≥ 3, and 1.73 m/s for F 4. CONCLUSION ARFI correlated with fibrosis stage and hyaluronic acid but not with inflammation. ARFI was affected by BMI, γ-glutamyltranspeptidase, and hyaluronic acid in each fibrosis stage.


Hepatology Research | 2008

Assessment of nutritional status of patients with hepatitis C virus-related liver cirrhosis

Naoto Kawabe; Senju Hashimoto; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Kyoko Kobayashi; Naruomi Komura; Hiroko Ito; Asako Niwa; Wakana Narita; Junko Hanashita; Ayako Ikeda; Kentaro Yoshioka

Aim:  Nutrition support for patients with liver cirrhosis, such as late evening snacks and branched‐chain amino acids, has been demonstrated to be effective. However, the assessment of the malnutrition of liver cirrhosis is still a problem. The aim of this study was to assess the nutritional status of patients with liver cirrhosis due to hepatitis C virus by six methods and to test the sensitivity and specificity of these methods.


World Journal of Gastroenterology | 2015

Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C

Keisuke Osakabe; Naohiro Ichino; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Ai Shibata; Wakana Asada; Naoto Kawabe; Senju Hashimoto; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Kazunori Nakaoka; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Kentaro Yoshioka

AIM To evaluate the changes of shear-wave velocity (Vs) by acoustic radiation force impulse after treatment in chronic hepatitis C. METHODS Eighty-seven patients with chronic hepatitis C were consecutively treated with combinations of interferon (IFN) plus ribavirin (RBV). Vs value (m/s) was measured with acoustic radiation force impulse before treatment, at end of treatment (EOT), 1 year after EOT, and 2 years after EOT. RESULTS In patients with a sustained virological response (SVR) (n = 41), Vs significantly decreased at EOT [1.19 (1.07-1.37), P = 0.0004], 1 year after EOT [1.10 (1.00-1.22), P = 0.0001], and 2 years after EOT [1.05 (0.95-1.16), P < 0.0001] compared with baseline [1.27 (1.11-1.49)]. In patients with a relapse (n = 26), Vs did not significantly decrease at EOT [1.23 (1.12-1.55)], 1 year after EOT [1.20 (1.12-1.80)], and 2 years after EOT [1.41 (1.08-2.01)] compared with baseline [1.39 (1.15-1.57)]. In patients with a nonvirological response (n = 20), Vs did not significantly decrease at EOT [1.64 (1.43-2.06)], 1 year after EOT [1.66 (1.30-1.95)], and 2 years after EOT [1.61 (1.36-2.37)] compared with baseline [1.80 (1.54-2.01)]. Among genotype 1 patients, baseline Vs was significantly lower in SVR patients [1.28 (1.04-1.40)] than in non-SVR patients [1.56 (1.20-1.83)] (P = 0.0142). CONCLUSION Reduction of Vs values was shown in SVR patients after IFN-plus-RBV therapy by acoustic radiation force impulse.


SpringerPlus | 2015

PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients

Kazunori Nakaoka; Senju Hashimoto; Naoto Kawabe; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Toru Nishikawa; Naohiro Ichino; Keisuke Osakabe; Kentaro Yoshioka

AimTo investigate associations between patatin-like phospholipase domain-containing 3 (PNPLA3) genotypes and fibrosis and hepatocarcinogenesis in Japanese chronic hepatitis C (CHC) patients.MethodsTwo hundred and thirty-one patients with CHC were examined for PNPLA3 genotypes, liver stiffness measurements (LSM), and hepatocellular carcinoma (HCC) from May 2010 to October 2012 at Fujita Health University Hospital. The rs738409 single nucleotide polymorphism (SNP) encoding for a functional PNPLA3 I148M protein variant was genotyped using a TaqMan predesigned SNP genotyping assay. LSM was determined as the velocity of a shear wave (Vs) with an acoustic radiation force impulse. Vs cut-off values for cirrhosis were set at 1.55 m/s. We excluded CHC patients with a sustained virological response or relapse after interferon treatment.ResultsPNPLA3 genotypes were CC, CG, and GG for 118, 72, and 41 patients, respectively. Multivariable logistic regression analysis selected older age (OR = 1.06; 95% CI: 1.03–1.09; p < 0.0001), higher body mass index (BMI) (OR= 1.12; 95% CI: 1.03–1.22; p = 0.0082), and PNPLA3 genotype GG (OR = 2.07; 95% CI: 0.97–4.42; p = 0.0599) as the factors independently associated with cirrhosis. When 137 patients without past history of interferon treatment were separately assessed, multivariable logistic regression analysis selected older age (OR = 1.05; 95% CI: 1.02–1.09; p = 0.0034), and PNPLA3 genotype GG (OR = 3.35; 95% CI: 1.13–9.91; p = 0.0291) as the factors independently associated with cirrhosis. Multivariable logistic regression analysis selected older age (OR = 1.12; 95% CI: 1.07–1.17; p < 0.0001), PNPLA3 genotype GG (OR = 2.62; 95% CI: 1.15–5.96; p = 0.0218), and male gender (OR = 1.83; 95% CI: 0.90–3.71); p = 0.0936) as the factors independently associated with HCC.ConclusionPNPLA3 genotype I148M is one of risk factors for developing HCC in Japanese CHC patients, and is one of risk factors for progress to cirrhosis in the patients without past history of interferon treatment.


World Journal of Hepatology | 2015

Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease

Aiko Fukui; Naoto Kawabe; Senju Hashimoto; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Kazunori Nakaoka; Masashi Ohki; Yuka Takagawa; Tomoki Takamura; Hiroyuki Kamei; Kentaro Yoshioka

AIM To evaluate the efficacy of vitamin E treatment on liver stiffness in nonalcoholic fatty liver disease (NAFLD). METHODS Thirty-eight NAFLD patients were administered vitamin E for > 1 year. The doses of vitamin E were 150, 300, or 600 mg; three times per day after each meal. Responses were assessed by liver enzyme levels [aspartate aminotransferase (AST), alanine aminotranferease (ALT), and γ-glutamyl transpeptidase (γ-GTP)], noninvasive scoring systems of hepatic fibrosis-4 [FIB-4 index and aspartate aminotransferase-to-platelet index (APRI)], and liver stiffness [velocity of shear wave (Vs)] measured by acoustic radiation force impulse elastography. Vs measurements were performed at baseline and 12 mo after baseline. The patients were genotyped for the patatin-like phospholipase domain containing 3 (PNPLA3) polymorphisms and then divided into either the CC/CG or GG group to examine each groups responses to vitamin E treatment. RESULTS We found marked differences in the platelet count, serum albumin levels, alkaline phosphatase levels, FIB-4 index, APRI, and Vs at baseline depending on the PNPLA3 polymorphism. AST, ALT, and γ-GTP levels (all P < 0.001); FIB-4 index (P = 0.035); APRI (P < 0.001); and Vs (P < 0.001) significantly decreased from baseline to 12 mo in the analysis of all patients. In the subset analyses of PNPLA3 genotypes, AST levels (P = 0.011), ALT levels (P < 0.001), γ-GTP levels (P = 0.005), APRI (P = 0.036), and Vs (P = 0.029) in genotype GG patients significantly improved, and AST and ALT levels (both P < 0.001), γ-GTP levels (P = 0.003), FIB-4 index (P = 0.017), and APRI (P < 0.001) in genotype CC/CG patients. CONCLUSION One year of vitamin E treatment improved noninvasive fibrosis scores and liver stiffness in NAFLD patients. The responses were similar between different PNPLA3 genotypes.

Collaboration


Dive into the Naoto Kawabe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takuji Nakano

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshiki Kan

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar

Masao Harata

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Masashi Ohki

Fujita Health University

View shared research outputs
Researchain Logo
Decentralizing Knowledge